What is the PLASMIC score and how is it used to assess the risk of thrombotic thrombocytopenic purpura (TTP)?

PLASMIC Score for TTP Risk Assessment

The PLASMIC score is a validated clinical prediction tool that uses seven readily available laboratory parameters to rapidly identify adults with suspected thrombotic microangiopathy who are likely to have severe ADAMTS13 deficiency (<10%) and require urgent plasma exchange, with scores ≥5 indicating intermediate-to-high risk warranting immediate empiric treatment while awaiting confirmatory testing. 1

Score Components and Calculation

The PLASMIC acronym represents seven clinical and laboratory variables, each contributing 0 or 1 point 1:

• Platelet count <30 × 10⁹/L (1 point)
• Combined hemolYsis variable: reticulocyte count >2.5% AND undetectable haptoglobin OR indirect bilirubin >2 mg/dL (1 point)
• Absence of active cancer (1 point)
• Absence of Stem-cell or solid-organ transplant (1 point)
• Mean corpuscular volume (MCV) <90 fL (1 point)
• International normalized ratio (INR) <1.5 (1 point)
• Creatinine <2.0 mg/dL (1 point)

Risk Stratification and Clinical Action

Scores are stratified into three risk categories that directly guide management decisions 1:

• Low risk (0-4 points): Very low probability of TTP; severe ADAMTS13 deficiency unlikely
• Intermediate risk (5 points): Moderate probability requiring clinical judgment
• High risk (6-7 points): High probability of TTP; severe ADAMTS13 deficiency likely

The KDIGO 2024 guidelines explicitly recommend starting plasma exchange and glucocorticoids in adults with intermediate-to-high PLASMIC scores (>5 points) while awaiting ADAMTS13 results, as rapid treatment initiation is critical for reducing mortality in TTP. 1

Diagnostic Performance

Meta-analysis demonstrates that a PLASMIC score ≥5 has exceptional sensitivity (99%) and negative predictive value (99% at 35% TTP prevalence), making it highly effective for ruling out TTP and avoiding unnecessary plasma exchange. 2

The specificity at this threshold is moderate (57%), meaning some patients without TTP will score positive, but this trade-off favors sensitivity to avoid missing life-threatening cases 2. A score ≥6 provides better specificity (89%) but reduced sensitivity (85%), which may miss some TTP cases. 2

Multiple validation studies confirm consistent performance across institutions 3, 4, 5:

• Sensitivity ranges from 87-100% for high-risk scores
• Negative predictive value consistently exceeds 95%
• The score discriminates severe ADAMTS13 deficiency with c-statistics of 0.94-0.99

Clinical Application Algorithm

When thrombotic microangiopathy is suspected based on thrombocytopenia, microangiopathic hemolytic anemia, and schistocytes on peripheral smear 6:

1. Immediately calculate the PLASMIC score using available laboratory data 1

2. Simultaneously order ADAMTS13 activity and anti-ADAMTS13 antibody testing 1

3. For scores >5 points in adults: Initiate plasma exchange and high-dose glucocorticoids immediately without waiting for ADAMTS13 results 1

4. For scores 0-4 points: Plasma exchange can reasonably be deferred while pursuing alternative TMA etiologies (antiphospholipid syndrome, complement-mediated TMA, drug-induced, malignancy-associated) 1, 2

5. Test for antiphospholipid antibodies concurrently to evaluate for APS nephropathy 1

Critical Pitfalls and Caveats

The PLASMIC score was derived and validated specifically for adults; in children, TTP is less common and plasma exchange carries higher morbidity, so deferring treatment for 24-48 hours until ADAMTS13 results are available is acceptable. 1

The score performs less reliably in certain populations 7:

• Elderly patients (>60 years) show reduced specificity (18% vs. 57% in younger patients), requiring more cautious interpretation
• Patients with lupus nephritis and TMA may have overlapping features that complicate scoring 1

A low PLASMIC score does not exclude early TMA, as schistocytes may be absent initially despite the test's low sensitivity for early disease. 6 Clinical judgment must override scoring when suspicion remains high based on clinical trajectory.

The score distinguishes TTP from other thrombotic microangiopathies but does not differentiate between immune TTP and congenital TTP—both require ADAMTS13 testing for definitive diagnosis. 8

Patients with low-intermediate PLASMIC scores (0-5) who receive empiric plasma exchange show no significant survival benefit, supporting the strategy of withholding treatment in this group. 5 This avoids unnecessary exposure to plasma exchange complications (catheter-related infections, citrate toxicity, allergic reactions).

The score's excellent negative predictive value (98-100%) makes it most valuable for ruling out TTP rather than ruling it in—a high score mandates treatment, but clinical context always supersedes scoring. 2, 5